CIMIT Gives Academic Community Voice In Least Burdensome Debate
This article was originally published in The Gray Sheet
Executive Summary
The Center for Innovative Minimally Invasive Therapy (CIMIT) is planning a public forum that will convene representatives from FDA, industry and the academic community to discuss the "least burdensome" process for device evaluation in several specific product areas.
You may also be interested in...
LBITF, FDA "Concept and Principles" Draft Attests Collaborative Effort
Reviewers of 510(k) premarket submissions should limit their analyses to claims "that present a major impact on the intended use of the device," according to principles set forth in a least burdensome industry task force (LBITF) and FDA draft document released for comment on FDA's website March 20.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.